{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:23:46Z","timestamp":1790871826182,"version":"4.1.0"},"reference-count":34,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2025,7,31]]},"DOI":"10.7883\/yoken.jjid.2024.372","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T22:09:26Z","timestamp":1753913366000},"source":"Crossref","is-referenced-by-count":3,"title":["Ensitrelvir for the treatment of COVID-19: A systematic review of evidence"],"prefix":"10.7883","author":[{"given":"Saeed","family":"Khorramnia","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, School of Medicine, Ali Ibn Abitaleb Educational and Treatment Hospital, Rafsanjan University of Medical Sciences, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Hamid","family":"Pakzad Moghadam","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, School of Medicine, Ali Ibn Abitaleb Educational and Treatment Hospital, Rafsanjan University of Medical Sciences, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Sarkoohi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, School of Medicine, Ali Ibn Abitaleb Educational and Treatment Hospital, Rafsanjan University of Medical Sciences, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Mohajeri Iravani","sequence":"additional","affiliation":[{"name":"School of Allied Medical Sciences, 503 Hospital (Hajar), AJA University of Medical Sciences, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Orandi","sequence":"additional","affiliation":[{"name":"School of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samrand","family":"Fattah Ghazi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care, School of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahla","family":"Noori Ardabili","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Atieh Hospital, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebadallah","family":"Shiri Malekabad","sequence":"additional","affiliation":[{"name":"School of Nursing, AJA University of Medical Sciences, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zia","family":"Navidi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, School of Medicine, Ali Ibn Abitaleb Educational and Treatment Hospital, Rafsanjan University of Medical Sciences, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4631","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Frediansyah A, Tiwari R, Sharun K, et al. Antivirals for COVID-19: a critical review. Epidemiol Glob Health. 2021;9:90-8.","DOI":"10.1016\/j.cegh.2020.07.006"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gudima G, Kofiadi I, Shilovskiy I, et al. Antiviral therapy of COVID-19. Int J Mol Sci. 2023;24(10):8867.","DOI":"10.3390\/ijms24108867"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Amani B, Amani B. Efficacy and safety of nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis. J Med Virol. 2023;95(2):e28441.","DOI":"10.1002\/jmv.28441"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fiolet T, Guihur A, Rebeaud ME, et al. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(1):19-27.","DOI":"10.1016\/j.cmi.2020.08.022"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ghazy RM, Almaghraby A, Shaaban R, et al. A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. Sci Rep. 2020;10(1):22139.","DOI":"10.1038\/s41598-020-77748-x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lee TC, Murthy S, Del Corpo O, et al. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(9):1203-10.","DOI":"10.1016\/j.cmi.2022.04.018"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Amani B, Amani B. Azvudine versus Paxlovid in COVID-19: A systematic review and meta-analysis. Rev Med Virol. 2024;34(4):e2551.","DOI":"10.1002\/rmv.2551"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Amani B, Amani B. Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis. PloS one. 2024;19(6):e0298772.","DOI":"10.1371\/journal.pone.0298772"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chan JFW, Yuan S, Chu H, et al. COVID-19 drug discovery and treatment options. Nat Rev Microbiol. 2024:1-17.","DOI":"10.1038\/s41579-024-01036-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Vitiello A, Zovi A, Rezza G. New emerging SARS-CoV-2 variants and antiviral agents. Drug Resist Updat. 2023;70:100986.","DOI":"10.1016\/j.drup.2023.100986"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Rauch S, Costacurta F, Sch\u00f6ppe H, et al. Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system. Antiviral Res. 2024;231:105969.","DOI":"10.1016\/j.antiviral.2024.105969"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lin M, Zeng X, Duan Y, et al. Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants. Commun Biol. 2023;6(1):694.","DOI":"10.1038\/s42003-023-05071-y"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kuroda T, Nobori H, Fukao K, et al. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo. J Antimicrob Chemother. 2023;78(4):946-52.","DOI":"10.1093\/jac\/dkad027"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kawashima S, Matsui Y, Adachi T, et al. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally. Biochemical and Biochem Biophys Res Commun. 2023;645:132-6.","DOI":"10.1016\/j.bbrc.2023.01.040"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. McCarthy MW. Ensitrelvir as a potential treatment for COVID-19. Expert Opin Pharmacother. 2022;23(18):1995-8.","DOI":"10.1080\/14656566.2022.2146493"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nobori H, Fukao K, Kuroda T, et al. Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model. J Antimicrob Chemother. 2022;77(11):2984-91.","DOI":"10.1093\/jac\/dkac257"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yotsuyanagi H, Ohmagari N, Doi Y, et al. Efficacy and safety of 5-day oral Ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial. JAMA Netw Open. 2024;7(2):e2354991.","DOI":"10.1001\/jamanetworkopen.2023.54991"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mukae H, Yotsuyanagi H, Ohmagari N, et al. Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study. Clin Infect Dis. 2023;76(8):1403-11.","DOI":"10.1093\/cid\/ciac933"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yoshida R, Sasaki T, Ohsaki Y. Real-world efficacy of ensitrelvir in hospitalized patients with covid-19 in Japan: a retrospective observational study. Cureus. 2024;16(5).","DOI":"10.7759\/cureus.61048"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Takazono T, Fujita S, Komeda T, et al. Real-world effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19. Infect Dis Ther. 2024;13(8):1821-33.","DOI":"10.1007\/s40121-024-01010-4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Shimizu R, Sonoyama T, Fukuhara T, et al. Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults. Antimicrob Agents Chemother. 2022;66(10):e00632-22.","DOI":"10.1128\/aac.00632-22"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Shimizu R, Sonoyama T, Fukuhara T, et al. A Phase 1 study of ensitrelvir fumaric acid tablets evaluating the safety, pharmacokinetics and food effect in healthy adult populations. Clin Drug Investig. 2023;43(10):785-97.","DOI":"10.1007\/s40261-023-01309-z"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mukae H, Yotsuyanagi H, Ohmagari N, et al. A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part. Antimicrob Agents Chemother. 2022;66(10):e00697-22.","DOI":"10.1128\/aac.00697-22"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ohmagari N, Yotsuyanagi H, Doi Y, et al. Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID-19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b\/3 Clinical Trial. Influenza Other Respir Viruses. 2024;18(6):e13338.","DOI":"10.1111\/irv.13338"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Luetkemeyer AF, Chew KW, Lacey S, et al. Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial. Clin Infect Dis. 2025:ciaf029.","DOI":"10.1093\/cid\/ciaf029"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Abe S, Wannigama DL, Suzuki Y, et al. Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series. New Microbes New Infect. 2024;62:101522.","DOI":"10.1016\/j.nmni.2024.101522"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Tomita T, Miyazawa S, Sonoyama T. Treatment with ensitrelvir for COVID-19 in hospitalized patients of very advanced age: Case series. Medicine. 2024;103(30):e39080.","DOI":"10.1097\/MD.0000000000039080"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Hayashi N, Tsukimura E, Ogura E. Ensitrelvir for the treatment of COVID-19: Final analysis of a post-marketing surveillance from Japan. J Infect Chemother. 2025;31(3):102574.","DOI":"10.1016\/j.jiac.2024.12.003"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge. N Engl J Med. 2022;387(9):790-8.","DOI":"10.1056\/NEJMoa2204919"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Sasaki M, Tabata K, Kishimoto M, et al. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. Sci Transl Med. 2022;15(679):eabq4064.","DOI":"10.1126\/scitranslmed.abq4064"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post\u2013COVID-19 condition. JAMA Intern Med. 2023;183(6):554-64.","DOI":"10.1001\/jamainternmed.2023.0743"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Gerhart J, Cox DS, Singh RSP, et al. A comprehensive review of the clinical pharmacokinetics, pharmacodynamics, and drug interactions of nirmatrelvir\/ritonavir. Clin Pharmacokinet. 2024;63(1):27-42.","DOI":"10.1007\/s40262-023-01339-y"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Lemaitre F, Gr\u00e9goire M, Monchaud C, et al. Management of drug-drug interactions with nirmatrelvir\/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT). Therapie. 2022;77(5):509-21.","DOI":"10.1016\/j.therap.2022.03.005"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Shimizu R, Sonoyama T, Fukuhara T, et al. Evaluation of the drug\u2013drug interaction potential of ensitrelvir fumaric acid with cytochrome P450 3A substrates in healthy Japanese adults. Clin Drug Investig. 2023;43(5):335-46.","DOI":"10.1007\/s40261-023-01265-8"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/advpub\/0\/advpub_JJID.2024.372\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:26:31Z","timestamp":1754108791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/advpub\/0\/advpub_JJID.2024.372\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2024.372","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"article-number":"JJID.2024.372"}}